Form 8-K · Current Report · Filed 2026-03-12
Halozyme Therapeutics Appoints David Ramsay as Interim CFO
Halozyme Therapeutics, Inc. announced on March 12, 2026, that David Ramsay has been appointed as the Interim Chief Financial Officer, effective March 23, 2026. Ramsay, who has previously served as the company's CFO from 2003-2009 and 2013-2015, will be responsible for overseeing financial operations during the search for a permanent CFO. He will receive a monthly salary of $50,000 and an equity grant of 10,000 restricted stock units, with additional units contingent on continued employment. The appointment was communicated via a press release issued the same day.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-26-000035
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$66.48
Next session
-4.2%
Since filing
+65.8%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.